Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee.

Greco R, Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, Sharrack B, Snowden JA, Tarte K, Onida F, Sánchez-Ortega I, Burman J, Castilla Llorente C, Cervera R, Ciceri F, Doria A, Henes J, Lindsay J, Mackensen A, Muraro PA, Ricart E, Rovira M, Zuckerman T, Yakoub-Agha I, Farge D (2024)

Publication Type: Journal article, Review article

Publication year: 2024

Journal

Book Volume: 69

DOI: 10.1016/j.eclinm.2024.102476

Abstract

Autoimmune diseases (ADs) are characterized by loss of immune tolerance, high chronicity, with substantial morbidity and mortality, despite conventional immunosuppression (IS) or targeted disease modifying therapies (DMTs), which usually require repeated administration. Recently, novel cellular therapies (CT), including mesenchymal stromal cells (MSC), Chimeric Antigen Receptors T cells (CART) and regulatory T cells (Tregs), have been successfully adopted in ADs. An international expert panel of the European Society for Blood and Marrow Transplantation and the International Society for the Cell and Gene Therapy, reviewed all available evidence, based on the current literature and expert practices, on use of MSC, CART and Tregs, in AD patients with rheumatological, neurological, and gastroenterological indications. Expert-based consensus and recommendations for best practice and quality of patient care were developed to support clinicians, scientists, and their multidisciplinary teams, as well as patients and care providers and will be regularly updated.

Authors with CRIS profile

Involved external institutions

Universitat de Barcelona (UB) / University of Barcelona Spain (ES) Technion - Israel Institute of Technology Israel (IL) Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille) France (FR) Hôpitaux Universitaires Saint-Louis, Lariboisière, Fernand-Widal France (FR) Università Vita-Salute San Raffaele (UniSR) Italy (IT) Berliner Institut für Gesundheitsforschung (BIH) Germany (DE) Università degli studi di Milano Italy (IT) Imperial College London / The Imperial College of Science, Technology and Medicine United Kingdom (GB) Careggi University Hospital / Azienda Ospedaliero Universitaria Careggi Italy (IT) Complejo Hospitalario de Salamanca / Complejo Asistencial Universitario de Salamanca Spain (ES) Centro de Investigación Biomédica en Red - Enfermedades Hepáticas y Digestivas (CIBERHD) Spain (ES) Sheffield Teaching Hospitals NHS Foundation Trust United Kingdom (GB) University of Sheffield United Kingdom (GB) Université de Rennes 1 / University of Rennes 1 France (FR) European Society for Blood and Marrow Transplantation EBMT Netherlands (NL) Uppsala University Sweden (SE) Institut Gustave-Roussy France (FR) Hospital Clínic de Barcelona Spain (ES) University of Padua / Universita degli Studi di Padova Italy (IT) Universitätsklinikum Tübingen Germany (DE) Royal London Hospital / London Infirmary United Kingdom (GB)

How to cite

APA:

Greco, R., Alexander, T., Del Papa, N., Müller, F., Saccardi, R., Sanchez-Guijo, F.,... Farge, D. (2024). Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. EClinicalMedicine, 69. https://doi.org/10.1016/j.eclinm.2024.102476

MLA:

Greco, Raffaella, et al. "Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee." EClinicalMedicine 69 (2024).

BibTeX: Download